TNG Share Price Performance
€0.76
0.14 (22.49%)
31.2% undervalued intrinsic discount
€1.10
Fair Value
Price €0.76
AnalystConsensusTarget €1.10
AnalystLowTarget €1.10
AnalystHighTarget €2.60
Fair Value€1.10
Share Pricen/a
Transgene SA Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
TNG Community Narratives
AN
Fair Value
·Fair Value €1.1 31.2% undervalued intrinsic discount
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value €1.1 31.2% undervalued intrinsic discount
High-Risk Clinical Trials And Rising Costs Will Delay Returns Yet Unlock Value
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value €2.6 70.9% undervalued intrinsic discount
Accelerated Aging And Healthcare Reforms Will Spark Immunotherapy Breakthroughs
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Key Takeaways Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities. Enhanced manufacturing capabilities are expected to improve net margins by reducing costs and increasing efficiency.Read more
AN
€1.1
31.2% undervalued intrinsic discount
Fair Value
Profit Margin
35.86%
Future PE
21.7x
Price in 2029
€1.33
High-Risk Clinical Trials And Rising Costs Will Delay Returns Yet Unlock Value
Key Takeaways Reliance on early-stage pipeline, extended clinical timelines, and delayed revenue risk are compounded by heavy R&D spending and ongoing losses without approved products. Competitive pressures, regulatory challenges, and dependence on external partnerships create uncertainty around commercialization prospects, long-term profitability, and future funding stability.Read more
AN
€1.1
31.2% undervalued intrinsic discount
Fair Value
Profit Margin
35.4%
Future PE
27.97x
Price in 2029
€1.33
Accelerated Aging And Healthcare Reforms Will Spark Immunotherapy Breakthroughs
Key Takeaways Accelerated trial success and regulatory pathways could lead to earlier revenue, with large pharma partnerships boosting near-term financial stability. Expanding pipeline and partnerships, driven by aging demographics and innovative technology, position Transgene for transformative, recurring revenue growth and higher margins.Read more
AN
€2.6
70.9% undervalued intrinsic discount
Fair Value
Profit Margin
28.39%
Future PE
27.37x
Price in 2028
€3.1
Trending Discussion
Recently Updated Narratives
AN
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Fair Value: €1.1 31.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Fair Value: €1.1 31.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Accelerated Aging And Healthcare Reforms Will Spark Immunotherapy Breakthroughs
Fair Value: €2.6 70.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Transgene SA Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 29, 2026
- -0.14
- -370.12%
- -520.44%
- 1.7%
About TNG
- Founded
- 1979
- Employees
- 145
- CEO
- WebsiteView website
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, and BioInvent. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
